ProCE Banner Activity

Phase I: BCMA-Targeted PHE885 CAR T-Cell Therapy With Rapid Manufacturing Time for R/R Multiple Myeloma

Conference Coverage
Slideset

Phase I results suggested that PHE855 was safe and effective BCMA-directed CAR T-cell therapy for patients with R/R multiple myeloma.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis